Dermatological Drugs - Southeast Asia

Southeast Asia

The market of Dermatological Drugs market in Southeast Asia is projected to achieve a significant revenue milestone, with an estimated value of US$233.10m in 2024.
Looking ahead, this market is anticipated to display a steady annual growth rate (CAGR 2024-2029) of 6.35%, leading to a substantial market volume of US$317.10m by 2029.
In terms of global comparison, United States is expected to generate the highest revenue, reaching an impressive US$11,670.00m in 2024.
In the Southeast Asian market for dermatological drugs, Singapore has emerged as a hub for innovative research and development, attracting leading pharmaceutical companies.

Key regions: United Kingdom, Canada, Japan, Europe, China

Market

Region

Region comparison

Currency

Analyst Opinion

The Dermatological Drugs market in Southeast Asia has been growing steadily in recent years, driven by various factors such as increasing disposable income, rising awareness of skin health, and a growing elderly population.

Customer preferences: Customers in Southeast Asia are becoming more aware of the importance of skin health, leading to an increased demand for dermatological drugs. In addition, the region's growing middle class with higher disposable incomes is also driving demand for premium skincare products.

Trends in the market: In Indonesia, the demand for dermatological drugs is driven by the high prevalence of skin diseases such as acne and eczema, as well as the popularity of skin-whitening products. In Thailand, the market is dominated by prescription drugs for treating skin diseases such as psoriasis and atopic dermatitis. In Malaysia, there is a growing demand for anti-aging products due to the country's aging population.

Local special circumstances: One unique aspect of the Southeast Asian market is the popularity of traditional herbal remedies for skin conditions. This has led to the development of a niche market for herbal-based dermatological products.

Underlying macroeconomic factors: The growing middle class in Southeast Asia with higher disposable incomes is a key driver of the dermatological drugs market. In addition, the region's aging population is also contributing to the growth of the anti-aging skincare market. The rise of medical tourism in the region is also boosting demand for dermatological drugs, as more people travel to Southeast Asia for affordable medical treatments.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.